In a streptozotocin-induced diabetic rat model, research is being done on the anti-diabetic potential of mangiferin. Mangiferin was given orally at doses of 200 mg/kg and 400 mg/kg, along with phytosome extracts (100 mg/kg and 200 mg/kg), and glibenclaimide (10 mg/kg), to diabetic rats caused by streptozotocin.. Diabetes-treated diabetic rats received mangiferin, which decreased blood glucose and haemoglobin levels while raising insulin and haemoglobin levels. Every parameter is operating normally. In the liver tissue of rats treated for diabetes, this activity diminished. These results showed that mangiferin has antidiabetic action in diabetic rats produced by STZ. Mangiferin's antidiabetic effects were compared to those of common antidiabetic medications.